Anaphylatoxins generated by complement activation by filter membranes are present in plasma during hemodialysis (HD). In the presence of endotoxins which may contaminate the dialysate, they can trigger monocytes to produce interleukin-1 (IL-1) and tumor necrosis factor (TNF), with detrimental effects for the patients. We have investigated whether or not the use of complement activating (cuprophan) and non- (or less-) activating membranes (polysulfone, polymethylmethacrylate or polyacrylonitrile) per se influences cytokine levels in HD patients. Our results indicate that if a sterile bicarbonate solution is used as dialysate, there are no significant increases in IL-1, TNF, interleukin-2 (IL-2) and soluble IL-2 receptors (sIL-2r) throughout HD, even with cuprophan membranes. Moreover even a prolonged use of this membrane (three months) did not change pre-dialysis levels of cytokines and receptors. Use of complement activating membranes also does not influence β2 microglobulin levels.
DinarelloC.S., KochK.M., ShaldonS.. Interleukin 1 and its relevance in patients treated with hemodialysis.Kidney Int1988; 33: S21–6.
2.
ShaldonS., LonnemannG., KochK.M.. Cytokine relevance in biocompatibility.Contrib Nephrol1989; 70: 227–36.
3.
OkusawaS., DinarelloC.A., YanceyK.B.C5a induction of human interleukin 1. Synergistic effect with endotoxins and interferon-gamma.J Immunol1987; 139: 2635–40.
4.
HakimR.M., FearonD.T., LazarusJ.M.. Biocompatibility of dialysis membranes: effects of chronic complement activation.Kidney Int1984; 26: 194–200.
5.
GardinaliM., CicardiM., AgostoniA., HugliT.E.. Complement activation in extracorporeal circulation, physiological and pathological implications.Pathol Immunopathol Res1986; 5: 352–70.
6.
HardingG.B., KleinE., PassT., WrightR., MillionC.. Endotoxin and bacterial contamination of dialysis center water and dialysate: a cross sectional survey.Int J Artif Organs1990; 13: 39–43.
7.
RoncoC.. Backfiltration in clinical dialysis: nature of the phenomenon, mechanism and possible solutions.Int J Artif Organs1990; 13: 11–21.
8.
ColtonK.E.. The interleukin hypothesis: a quantitative assessment.Kidney Int1988; 33: S27–9.
9.
TraceyK.J., LoweryS.F., CeramiA.. Cachectin/TNF alpha in septic shock and septic ARDS.Am Rev Respir Dis1988; 138: 1377–9.
10.
Haeffner-CavaillonN., CavaillonJ.M., CiancioniC., BacleF., DelousS., KazatchineM.D.. In vivo modulation of interleukin-1 during hemodialysis.Kidney Int1989; 35: 1212–8.
11.
BlumensteinM., Ziegler-HeitbrockH.W.L., SchillerB., SchmidtB., WardR.A., GurlandH.I.. Differential activation of monocytes in haemodialysis patients exposed to different types of membranes.Scand J Immunol1990; 31: 183–90.
12.
Haeffner-CavaillonN., FischerE., BacieF.Complement activation and induction of interleukin 1 production during hemodialysis.Contrib Nephrol1988; 62: 86–98.
13.
Chollet-MartinS., StamatakisG., BaillyS., MeryJ.P., Gougerot-PocidaloM.A.. Induction of tumour necrosis factor-α during haemodialysis. Influence of the membrane type.Clin Exp Immunol1991; 83: 329–32.
14.
LugerA., KovarikJ., StummvolH.K., UrbanskaA., LugerT.. Blood membrane interaction in haemodialysis leads to increased cytokine production.Kidney Int1987; 32: 84–8.
15.
HerbelinA., NguyenA.T., ZingraffJ., UrenaP., Deschamps-LatschaB.. Influence of uremia and hemodialysis on circulating interleukin 1 and tumour necrosis factor-α.Kidney Int1990; 37: 116–25.
16.
BingelM., LonnemannG., KochK.M., DinarelloC.A., ShaldonS.. Enhancement of in vitro interleukin-1 production by sodium-acetate.Lancet1987; i: 14–6.
17.
CollinsT., LapierreL.A., FiersW., StromingerJ.L., PoberJ.S.. Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A, B antigens in vascular endothelial cells and dermal fibroblast in vitro.Proc Natl Acad Sci USA1986; 83: 446–50.
18.
ZaouiP.M., StoneW.J., HakimR.M.. Effects of dialysis membrane on β2 microglobulin production and cellular expression.Kidney Int1990; 38: 962–8.
19.
KnudsenP.J., ShaldonS., FloegeJ., KochM.. Hemodialysis-related induction of β2 microglobulin synthesis and release by mononuclear phagocytes.Int J Artif Organs1990; 13: 73–6.
20.
BrancaccioD.. β2 microglobulin amyloidosis and osteoarticular pathology of the uremic patient on regular dialysis.Contrib Nephrol1990; 77: 177–86.
21.
GorevicP.D., CaseyT.T., StoneW.J., Di RaimondoC.R., PrelliF.C.. Frangione B. Beta2 microglobulin is an amyloidogenic protein in man.J Clin Invest1985; 76: 2425–9.
22.
BergstromJ., WehleB.. No change in corrected beta2 microglobulin concentration after cuprophane hemodialysis.Lancet1987; i: 925–6.
23.
CheungA.K., ParkerC.J., WilcoxL.A., JanatovaJ.. Activation of complement by hemodialysis membranes: polyacrylonitrile binds more C3a than cuprophan.Kidney Int1990; 37: 1055–9.
24.
ChenowethD.E.. The properties of human C5a anaphylatoxin. The significance of C5a formation during HD.Contrib Nephrol1987; 59: 51–71.
25.
ChenowethD.E., GoodmanM.G.. The C5a receptor of neutrophils and macrophages.Agents Actions1983; (Suppl) 12: 252–73.
26.
HueyR., HugliT.E.. Characterization of a C5a receptor on human polymorphonuclear leukocytes (PMN).J Immunol1985: 135: 2063–8.
27.
TettaC., FidelioT., LicataC.Production of tumor necrosis factor-alpha in patients on hemodiafiltration.Nephron1992: 61: 135–8.
28.
CannonJ.G., TompkinsR.G., GelfandJ.A.Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever.J Infect Dis1990; 161: 79–84.
29.
BommerJ., RitzE.. Water quality — a neglected problem in hemodialysis.Nephron1987; 46: 1–6.
30.
Association for the Advancement of Medical Instrumentation: hemodialysis systems standard (proposal).Arlington1978.
31.
LonnemannG., BingelM., FloegeJ.Detection of endotoxin-like interleukin 1 inducing activity during in vitro dialysis.Kidney Int1988; 33: 29–35.
32.
SchindlerR., LonnemannG., ShaldonS.Transcription, not synthesis, of interleukin 1 and tumor necrosis factor by complement.Kidney Int1990; 37: 85–93.
33.
SchindlerR., LinnenweberS., SchulzeM.Gene expression of interleukin-1β during hemodiaysis.Kidney Int1993; 43: 712–21.
34.
StitesD.P., StoboJ.D., WellsJ.V.. Basic and clinical immunology, 7th Edition. Norwalk: Appleton and Lange, 1986; 82–95.
